(N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}sulfuric diamide) | 1148047-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: (N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}sulfuric diamide)
• 英文别名: N-[4-(5-phenanthren-2-yl-3-trifluoromethyl-pyrazol-1-yl)-phenyl]-aminosulfonamide；5-phenanthren-2-yl-1-[4-(sulfamoylamino)phenyl]-3-(trifluoromethyl)pyrazole
• CAS: 1148047-04-4
• 化学式: C₂₄H₁₇F₃N₄O₂S
• 分子量: 482.486
• InChiKey: KFRALURJXUBCFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  98.4
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮 在 盐酸 、 platinum(IV) oxide 、 氢气 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}sulfuric diamide)
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018

文献信息

• Anti-staphylococcal celecoxib derivatives
  申请人：Chen Ching-Shih

  公开号：US09079899B2

  公开（公告）日：2015-07-14

  A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.

  本文描述了一种通过给予含有公式I的Celecoxib衍生物或其药学上可接受的盐的药物组合物来治疗受金黄色葡萄球菌感染的受体的方法。同时，本文也描述了制备多种Celecoxib衍生物以测试其作为潜在抗金黄色葡萄球菌药物的能力。
• Compositions and methods for inhibiting the growth of multi-drug resistant microbes
  申请人：Ohio State Innovation Foundation

  公开号：US10028933B2

  公开（公告）日：2018-07-24

  Compositions and methods for preventing and treating infection with multi-drug resistant bacteria with AR-13 alone or in combination with antibiotics are provided.

  提供了单独使用 AR-13 或与抗生素联合使用 AR-13 预防和治疗多重耐药菌感染的组合物和方法。
• ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES
  申请人：The Ohio State University Research Foundation

  公开号：EP2635274B1

  公开（公告）日：2017-12-06
• ANTIBACTERIAL PROTEIN KINASE INHIBITORS
  申请人：The Ohio State University

  公开号：US20150258100A1

  公开（公告）日：2015-09-17

  Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.
• COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF MULTI-DRUG RESISTANT MICROBES
  申请人：Ohio State Innovation Foundation

  公开号：US20170020846A1

  公开（公告）日：2017-01-26

  Compositions and methods for preventing and treating infection with multi-drug resistant bacteria with AR-13 alone or in combination with antibiotics are provided.